Verubecestat
Solid powder
Inhibitors/Agonists
Verubecestat is a small molecule inhibitor that targets beta-secretase 1 (BACE1), an enzyme that plays a crucial role in the production of amyloid beta (Aβ) peptides. Aβ peptides are known to accumulate in the brains of Alzheimer's disease patients, leading to the formation of plaques and neurodegeneration. Verubecestat has been developed as a potential therapeutic agent for Alzheimer's disease, and its chemical structure, biological activity, and potential applications have been extensively studied.
409.41
409.41
Formulation:
409.41
Source:
Usage:
Verubecestat
The product is for non-human research only. Not for therapeutic or veterinary use.
Catalog Number: BT-253591
CAS Number: 1286770-55-5
Molecular Formula: C₁₇H₁₇F₂N₅O₃S
Molecular Weight: 409.41
Purity: ≥ 99%
Inventory: In Stock
| Size | SKU | Price | |
|---|---|---|---|
| 5mg | bt-253591-5mg | $433.38 |
| CAS Number | 1286770-55-5 |
|---|---|
| Product Name | Verubecestat |
| Molecular Formula | C₁₇H₁₇F₂N₅O₃S |
| Molecular Weight | 409.41 |
| Appearance | Solid powder |
| InChI | InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1 |
| InChI Key | YHYKUSGACIYRML-KRWDZBQOSA-N |
| IUPAC Name | N-[3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-6H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide |
| Description | Verubecestat is a small molecule inhibitor that targets beta-secretase 1 (BACE1), an enzyme that plays a crucial role in the production of amyloid beta (Aβ) peptides. Aβ peptides are known to accumulate in the brains of Alzheimer's disease patients, leading to the formation of plaques and neurodegeneration. Verubecestat has been developed as a potential therapeutic agent for Alzheimer's disease, and its chemical structure, biological activity, and potential applications have been extensively studied. |
| Method of Synthesis or Extraction | Verubecestat can be synthesized using several methods, including the condensation of an amine and an aldehyde, followed by cyclization and reduction. Another method involves the reaction of an amine and an isocyanate, followed by cyclization and reduction. The efficiency and yield of each method depend on the starting materials, reaction conditions, and purification methods used. Environmental and safety considerations are also important, as some of the starting materials and reagents used in the synthesis of verubecestat may be hazardous or toxic. |
| Chemical Structure and Biological Activity | Verubecestat has a molecular weight of 465.6 g/mol and a chemical formula of C24H26F2N4O3. It is a white to off-white crystalline powder that is soluble in organic solvents. Verubecestat inhibits Verubecestat by binding to its active site, preventing the cleavage of amyloid precursor protein (APP) and the production of Aβ peptides. Verubecestat has been shown to reduce Aβ levels in the brains of animal models and human patients with Alzheimer's disease, indicating its potential as a disease-modifying therapy. |
| Biological Effects | Verubecestat has been shown to have several biological effects on cell function and signal transduction. It reduces the production of Aβ peptides, which are known to be toxic to neurons and cause neuroinflammation. Verubecestat also modulates the activity of several signaling pathways, including the Notch signaling pathway, which is involved in cell differentiation and proliferation. However, verubecestat may also have potential toxic effects, as it may interfere with the normal function of Verubecestat in other tissues and organs. |
| Applications | Verubecestat has potential applications in medical research, environmental research, and industrial research. In medical research, verubecestat is being studied as a potential therapeutic agent for Alzheimer's disease. Clinical trials have shown promising results, with verubecestat reducing Aβ levels in the brains of patients with mild to moderate Alzheimer's disease. However, the long-term safety and efficacy of verubecestat are still being evaluated. In environmental research, verubecestat may have effects on ecosystems and pollution management, as it may interfere with the normal function of Verubecestat in non-target organisms. In industrial research, verubecestat may be used in manufacturing processes to improve product quality and efficiency, but health and safety considerations must be taken into account. |
| Future Perspectives and Challenges | Verubecestat has several limitations in its use and study, including its potential toxic effects, its specificity for Verubecestat, and its ability to cross the blood-brain barrier. Possible solutions and improvements include the development of more selective Verubecestat inhibitors, the use of combination therapies, and the optimization of dosing and administration. Future trends and prospects in the application of verubecestat in scientific research include the identification of new targets and pathways involved in Alzheimer's disease, the development of biomarkers for disease diagnosis and monitoring, and the integration of verubecestat into personalized medicine approaches. |
| SMILES | CC1(CS(=O)(=O)N(C(=N1)N)C)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)F)F |
| Synonyms | (R)-5-fluoro-N-(4-fluoro-3-(3-imino-2,5-dimethyl-1,1-dioxido-1,2,4-thiadiazinan-5-yl)phenyl)picolinamide 2,2,2-trifluoroacetate |
| Reference | 1:Merck ends trial of potential Alzheimer/'s drug verubecestat. Hawkes N.BMJ. 2017 Feb 15;356:j845. doi: 10.1136/bmj.j845. No abstract available. PMID: 28202490 2:Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer/'s Disease. Thaisrivongs DA, Miller SP, Molinaro C, Chen Q, Song ZJ, Tan L, Chen L, Chen W, Lekhal A, Pulicare SK, Xu Y.Org Lett. 2016 Nov 18;18(22):5780-5783. Epub 2016 Nov 4. PMID: 27934506 |
| PubChem Compound | Verubecestat |
| Last Modified | May 30 2023 |